Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity

Radiotherapy (RT) has been used to control tumors by physically damaging DNA and inducing apoptosis; it also promotes antitumor immune responses via neoantigens release and augmenting immune-oncology agents to elicit systemic response. Tumor regression after RT can recruit inflammatory cells, such a...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Ahmed I. Younes, Hampartsoum B. Barsoumian, Duygu Sezen, Vivek Verma, Roshal Patel, Mark Wasley, Yun Hu, Joe D. Dunn, Kewen He, Dawei Chen, Hari Menon, Fatemeh Masrorpour, Meidi Gu, Liangpeng Yang, Nahum Puebla-Osorio, Maria Angelica Cortez, James W. Welsh
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2021-02-01
Ráidu:	Translational Oncology
Fáttát:	Cancer Radiotherapy Abscopal effect TLR9 agonist CMP-001
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S1936523320304757
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!